[ST Renfu: HW281171 tablets received drug clinical trial approval notice] On November 10th, ST Renfu (600079.SH) announced that the company's wholly-owned subsidiary Hubei Biomedical Industry Technology Research Institute Co., Ltd. recently received the "Drug Clinical Trial Approval Notice" for HW281171 tablets approved and issued by the National Medical Products Administration. The drug is registered as a Class 1 chemical drug and is intended to be used for the treatment of chronic urticaria. It is a new oral small molecule drug. Up to now, the cumulative R&D investment in this project is approximately 30 million yuan. According to Insight database statistics, there are currently no drugs with the same target and same indication on the market in China, and two companies have entered the Phase I clinical stage.